Cash Flow Statement (Annual)
ENV / Envestnet, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities|
|Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Depreciation Depletion And Amortization||4,499||5,703||6,376||12,400||15,329||18,651||27,962||63,999||62,820|
|Increase Decrease In Deferred Charges||-||-||-||-||-||-275||-1,819||438||-1,027|
|Provision For Doubtful Accounts||385||2,668||-||-||203||15||176||1,122||867|
|Deferred Income Taxes And Tax Credits||1,572||1,215||2,162||83||-2,546||-4,640||-10,508||5,584||-4,597|
|Share Based Compensation||780||1,731||3,062||4,342||8,738||11,423||15,161||33,276||31,331|
|Interest Expense Debt||-||-||-||-||-||626||10,271||8,244||8,994|
|Payment For Contingent Consideration Liability Operating Activities||-||-||-||-||-||-||-||-||-|
|Income Loss From Equity Method Investments||-||-||-||-||-||-||-||-1,420||-1,469|
|Gain Loss On Disposition Of Assets||-||-||-||-||-||-||-||-398||-76|
|Increase Decrease In Operating Assets|
|Increase Decrease In Accounts Receivable||1,338||3,718||-1,940||-1,017||9,566||-1,788||9,297||-1,646||8,121|
|Increase Decrease In Prepaid Deferred Expense And Other Assets||148||599||1,988||-4,645||1,075||-9,733||-14,716||3,290||787|
|Increase Decrease In Other Noncurrent Assets||-42||52||1,006||188||1,444||873||6,025||98||1,690|
|Increase Decrease In Accrued Liabilities||38||2,437||802||3,100||12,389||9,784||-13,653||17,174||16,810|
|Increase Decrease In Accounts Payable||-475||-185||267||640||2,914||-659||3,128||-462||-442|
|Increase Decrease In Deferred Revenue||-187||208||-507||1,028||1,625||4,677||10,906||2,014||1,191|
|Increase Decrease In Other Operating Liabilities||68||137||-39||1,166||1,074||26||-3,792||3,776||2,427|
|Net Cash Provided By Used In Operating Activities||8,365||1,467||24,721||28,541||-||-||42,035||81,270||108,607|
|Net Cash Provided By Used In Investing Activities|
|Payments To Acquire Property Plant And Equipment||3,078||4,169||4,798||4,838||6,125||6,177||9,184||13,967||14,945|
|Payments To Develop Software||1,306||1,340||1,482||2,350||3,143||3,382||5,532||8,609||12,624|
|Payments To Acquire Businesses Net Of Cash Acquired||-||917||23,719||62,352||8,992||59,570||328,305||31,613||-|
|Net Cash Provided By Used In Investing Activities||-5,040||-5,501||-30,133||-69,707||-||-||-344,621||-57,927||-29,019|
|Net Cash Provided By Used In Financing Activities|
|Proceeds From Long Term Lines Of Credit||-||-||-||-||-||30,000||10,000||40,000||35,000|
|Repayments Of Long Term Lines Of Credit||-||-||-||-||-||30,000||10,000||40,000||62,500|
|Payment For Contingent Consideration Liability Financing Activities||-||-||-||-||-||6,000||7,219||3,729||2,286|
|Payments To Acquire Businesses Gross||-||-||-||-||-||-||-||-||445|
|Repayments Of Secured Debt||-||-||-||-||-||-||10,000||8,000||35,862|
|Proceeds From Stock Options Exercised||3||1,925||2,747||2,069||6,400||5,190||8,279||4,924||7,951|
|Payments Related To Tax Withholding For Share Based Compensation||-||-||-||-||622||2,062||7,412||10,966||13,974|
|Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans||-||-||-||2,759||1||1||2||6||5|
|Net Cash Provided By Used In Financing Activities||-245||40,177||2,653||6,240||-||-||144,550||-22,469||-72,440|
|Effect Of Exchange Rate On Cash And Cash Equivalents||-||-||-||-||-||-||-||-||375|
|Cash And Cash Equivalents Period Increase Decrease||3,080||36,143||-2,759||-34,926||-||-||-158,036||874||7,523|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents||-||-||-||-||-||-||-||-||-|
|Income Taxes Paid Net||240||171||813||796||4,708||2,131||1,700||1,114||3,261|
|Interest Paid Net||-||-||-||-||-||-||3,877||8,356||7,353|
|Supplemental Cash Flow Information|
|Purchase Liabilities Included In Accrued Expenses Not Yet Paid||-||-||-||-||-||-||13,676||996||856|
|Accrued Payment To Fund Deferred Compensation Liability Included In Accounts Payable||-||-||-||-||-||-||-||-||-|
|Capital Expenditures Incurred But Not Yet Paid||-||-||-||-||-||158||-||1,136||1,286|
Peers - Business Services, Not Elsewhere Classified (7389)
BID / Sotheby's
BR / Broadridge Financial Solutions, Inc.
CBZ / CBIZ, Inc.
FDC / First Data Corporation
FICO / Fair Isaac Corp.
FIS / Fidelity National Information Services, Inc.
FLT / FleetCor Technologies, Inc.
GRUB / GrubHub Inc.
LC / LendingClub Corp.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET